LT4011B - Cerebral neurothropic factor - Google Patents

Cerebral neurothropic factor Download PDF

Info

Publication number
LT4011B
LT4011B LTIP1546A LTIP1546A LT4011B LT 4011 B LT4011 B LT 4011B LT IP1546 A LTIP1546 A LT IP1546A LT IP1546 A LTIP1546 A LT IP1546A LT 4011 B LT4011 B LT 4011B
Authority
LT
Lithuania
Prior art keywords
bdnf
ngf
protein
derivative
neurons
Prior art date
Application number
LTIP1546A
Other languages
English (en)
Lithuanian (lt)
Inventor
Carolin Hyman
Ralph Alderson
George D Yancopoulos
Yves-Alain Barde
Hans Friedrich Erwin Thoenen
Andreas Hohn
Friedrich Lottspeich
Ronald M Lindsay
Magdalena Hofer
Loachim Leibrock
David Harold Edgar
Bastian Hengerer
Dan Lindholm
Francisco Zafra
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of LTIP1546A publication Critical patent/LTIP1546A/xx
Publication of LT4011B publication Critical patent/LT4011B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
LTIP1546A 1989-08-30 1993-12-07 Cerebral neurothropic factor LT4011B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor

Publications (2)

Publication Number Publication Date
LTIP1546A LTIP1546A (en) 1995-07-25
LT4011B true LT4011B (en) 1996-08-26

Family

ID=23584217

Family Applications (2)

Application Number Title Priority Date Filing Date
LTIP1546A LT4011B (en) 1989-08-30 1993-12-07 Cerebral neurothropic factor
LTIP1818A LT4063B (en) 1989-08-30 1994-01-28 A gene encoding neurotrophin-3, gene products and process for preparing thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTIP1818A LT4063B (en) 1989-08-30 1994-01-28 A gene encoding neurotrophin-3, gene products and process for preparing thereof

Country Status (8)

Country Link
US (2) US5180820A (ja)
JP (1) JP2783450B2 (ja)
CZ (1) CZ285649B6 (ja)
DD (2) DD299196A5 (ja)
GR (1) GR1002052B (ja)
LT (2) LT4011B (ja)
RU (2) RU2131926C1 (ja)
ZA (2) ZA906927B (ja)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US6933276B1 (en) 1989-08-30 2005-08-23 Regeneron Pharmaceuticals, Inc. Methods of treating peripheral neuropathies using neurotrophin-3
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
FR2671487B1 (fr) * 1991-01-14 1993-03-19 Oreal Utilisation d'un facteur de croissance dans une composition amincissante.
WO1995012982A1 (en) * 1993-11-09 1995-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogeneous neuronal cell transplants
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
ES2113574T3 (es) * 1993-06-01 1998-05-01 Ono Pharmaceutical Co Derivados del acido pentanoico.
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
CA2204789C (en) * 1994-11-10 2002-11-12 Paul Ashton Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
TR199901734T2 (xx) * 1996-11-15 2000-01-21 Genentech, Inc. N�rotrofinlerin ar�t�lmas�.
NZ336865A (en) 1997-01-23 2001-01-26 Sumitomo Pharma Use of a therapeutic agent containing a neurotrophic factor for treatment of diabetes and hyperlipemia
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6391544B1 (en) * 1998-05-15 2002-05-21 Abbott Laboratories Method for using unequal primer concentrations for generating nucleic acid amplification products
ES2316194T3 (es) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4.
JP2000169389A (ja) * 1998-12-08 2000-06-20 Sumitomo Pharmaceut Co Ltd 触覚異常治療剤
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
DE10291524D2 (de) * 2001-04-06 2004-07-01 Anker Thorsten Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
EP2211183B1 (en) * 2003-11-19 2013-03-06 Satoris, Inc. Method for diagnosis and monitoring of Alzheimer's disease
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7037698B2 (en) 2004-05-19 2006-05-02 Amano Enzyme Inc. Pyrroloquinoline quinone-dependent glucose dehydrogenase
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
KR101245462B1 (ko) 2005-07-08 2013-03-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｐ35 항체 및 그의 용도
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
JP5279504B2 (ja) * 2006-11-17 2013-09-04 一般財団法人阪大微生物病研究会 神経伸長促進剤および伸長阻害剤
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
US20100112565A1 (en) * 2008-11-03 2010-05-06 Life Technologies Corporation Methods, kits, and reaction mixtures for high resolution melt genotyping
US20100112557A1 (en) * 2008-11-03 2010-05-06 Applied Biosystems Inc. Method for high resolution melt genotyping
EP2376122A2 (en) 2009-01-12 2011-10-19 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
ES2762610T3 (es) * 2009-02-12 2020-05-25 Curna Inc Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
RU2606012C2 (ru) * 2009-11-09 2017-01-10 Дженепод Терапевтикс Аб Новая вирусная векторная конструкция для нейронспецифического оптимизированного непрерывного синтеза dopa in vivo
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646007B1 (en) 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
EP3711778B1 (en) 2011-12-02 2024-05-08 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
JP2015511494A (ja) * 2012-03-15 2015-04-20 キュアナ，インク． 脳由来神経栄養因子（ｂｄｎｆ）に対する天然アンチセンス転写物の阻害によるｂｄｎｆ関連の疾患の処置
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3302524B1 (en) 2015-05-27 2020-09-23 Neurotech USA, Inc. Use of encapsulated cell therapy for treatment of glaucoma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
US4680262A (en) * 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
WO1989001940A1 (en) * 1987-09-04 1989-03-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
AU4803890A (en) * 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
JP2877509B2 (ja) * 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
EP0414151B1 (en) * 1989-08-21 1995-03-15 Takeda Chemical Industries, Ltd. Production of human nerve growth factor proteins
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
DK0550665T3 (da) * 1990-09-25 1996-12-02 Genentech Inc Ny neurotrofisk faktor
US7020718B2 (en) 2000-05-15 2006-03-28 Hewlett-Packard Development Company, L.P. System and method of aggregating discontiguous address ranges into addresses and masks using a plurality of repeating address blocks

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CARR VM, SIMPSON SB.: "Jr Proliferative and degenerative events in the early development of chick dorsal root ganglia. I. Normal development", J COMP NEUROL., 1978, pages 727 - 739
COWAN WM ET AL.: "Regressive events in neurogenesis.", SCIENCE, 1984, pages 1258 - 1265
HEUMANN R ET AL.: "Thoenen H. Relationship between levels of nerve growth factor (NGF) and its messenger RNA in sympathetic ganglia and peripheral target tissues", EMBO J., 1984, pages 3183 - 3189
HOLLYDAY M, HAMBURGER V.: "Reduction of the naturally occurring motor neuron loss by enlargement of the periphery", J COMP NEUROL., 1976, pages 311 - 320
J M CAPASSO, C B HIRSCHBERG: "Mechanisms of glycosylation and sulfation in the Golgi apparatus: evidence for nucleotide sugar/nucleoside monophosphate and nucleotide sulfate/nucleoside monophosphate antiports in the Golgi apparatus membrane", PROC NATL ACAD SCI USA., 1984, pages 7051 - 7055
K. SUDA, Y. A. BARDE, H. THOENEN: "Nerve growth factor in mouse and rat serum: Correlation between bioassay and radioimmunoassay determinations", PROC. NATI. ACAD. SCI. USA, 1978, pages 4042 - 4046
KORSCHING S, THOENEN H.: "Nerve growth factor supply for sensory neurons: site of origin and competition with the sympathetic nervous system", NEUROSCI LETT., 1985, pages 201 - 205, XP026760550, DOI: doi:10.1016/S0304-3940(85)80079-3
L. LANDMESSER, G. PILAR: "Fate of ganglionic synapses and ganglion cell axons during normal and induced cell death.", J. CELL BIOL., 1976, pages 357 - 374
LEVI-MONTALCINI R, BOOKER B.: "Excessive growth of the sympathetic ganglia evoked by a protein isolated from mouse salivary glands", PROC NATL ACAD SCI USA., 1960, pages 373 - 384
RITA LEVI-MONTALCINI, BARBARA BOOKER: "Destruction of the sympathetic ganglia in mammals by an antiserum to a nerve-growth protein", PROC NATL ACAD SCI USA., 1960, pages 384 - 391, XP055351278
S. KORSCHING, H. THOENEN: "Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation", PROC NATL ACAD SCI USA., 1983, pages 3513 - 3516, XP001161147, DOI: doi:10.1073/pnas.80.11.3513
THOENEN H, BANDTLOW C, HEUMANN R.: "The physiological function of nerve growth factor in the central nervous system: comparison with the periphery", REV PHYSIOL BIOCHEM PHARMACOL., 1987, pages 145 - 178
THOENEN H, BARDE YA.: "Physiology of nerve growth factor", PHYSIOL REV., 1980, pages 1284 - 1335
VIKTOR HAMBURGER: "The effects of wing bud extirpation on the development of the central nervous system in chick embryos", JOURNAL OF EXPERIMENTAL ZOOLOGY, 1934, pages 449

Also Published As

Publication number Publication date
JP2783450B2 (ja) 1998-08-06
GR900100653A (el) 1991-12-30
LT4063B (en) 1996-11-25
ZA906927B (en) 1991-06-26
LTIP1818A (en) 1995-09-25
US5180820A (en) 1993-01-19
CZ422990A3 (cs) 1999-06-16
RU2131926C1 (ru) 1999-06-20
CZ285649B6 (cs) 1999-10-13
GR1002052B (en) 1995-11-20
ZA906926B (en) 1991-06-26
DD299196A5 (de) 1992-04-02
RU2128226C1 (ru) 1999-03-27
DD299197A5 (de) 1992-04-02
LTIP1546A (en) 1995-07-25
JPH05328974A (ja) 1993-12-14
US5453361A (en) 1995-09-26

Similar Documents

Publication Publication Date Title
LT4011B (en) Cerebral neurothropic factor
US5229500A (en) Brain derived neurotrophic factor
RU2304585C2 (ru) Очищенный иммуногенный белок, его фрагменты и производные
Henderson et al. Localization of CNTF immunoreactivity to neurons and astroglia in the CNS
JPH05199879A (ja) 毛様体神経栄養因子
JPH05161493A (ja) ニューロトロフィン―３
Henderson et al. Localization of CNTF immunoreactivity to neurons and astroglia
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: REGENERON PHARMACEUTICALS, INC., US

Effective date: 20030122

MM9A Lapsed patents

Effective date: 20111207